Esperion Acquires Corstasis, Eyes Expansion into Rare Disease Markets
Event summary
- Esperion reported FY25 revenue of $403.1 million, a 21% increase year-over-year, with U.S. net product revenue growing 38% to $159.6 million.
- Q4 2025 revenue reached $168.4 million, a 144% increase year-over-year, and U.S. net product revenue was $43.7 million, up 38%.
- Esperion has agreed to acquire Corstasis Therapeutics, gaining access to Enbumyst™ (bumetanide nasal spray), a treatment for edema associated with congestive heart failure.
- The acquisition of Corstasis is estimated to target a $4 billion U.S. market opportunity for Enbumyst™.
- Esperion expects full year 2026 operating expenses to be in the range of $225 million to $255 million.
The big picture
Esperion's acquisition of Corstasis represents a strategic pivot towards expanding its product portfolio beyond its core bempedoic acid franchise and into the larger, underserved market for edema treatment. This move, coupled with the ambitious 'Vision 2040' plan, signals an intent to transform Esperion into a more diversified, innovation-driven company, but also introduces integration and execution risks. The company's reliance on partnerships for global expansion highlights the complexities of navigating international markets in the pharmaceutical sector.
What we're watching
- Integration Risk
- The success of the Corstasis acquisition hinges on Esperion’s ability to effectively integrate the new business and leverage its commercial infrastructure, which could be complicated by differing operational cultures and sales strategies.
- Patent Defense
- While settlements have removed immediate generic challenges, the remaining patent litigation and impending expirations in 2036 and 2040 pose a long-term threat to Esperion’s revenue stream and necessitate continued investment in patent protection.
- Pipeline Progress
- The advancement of Esperion’s oral triple combination lipid-lowering program, targeting a 2027 commercialization date, will be critical to sustaining growth beyond existing products and competing with established therapies.
Related topics